{"id":27937,"date":"2025-03-22T00:53:38","date_gmt":"2025-03-21T23:53:38","guid":{"rendered":"https:\/\/inmuno.es\/index.php\/2025\/03\/22\/can-autoimmune-disease-be-cured-by-deep-cd19-cell-depletion\/"},"modified":"2025-03-22T00:53:38","modified_gmt":"2025-03-21T23:53:38","slug":"can-autoimmune-disease-be-cured-by-deep-cd19-cell-depletion","status":"publish","type":"post","link":"https:\/\/inmuno.es\/index.php\/2025\/03\/22\/can-autoimmune-disease-be-cured-by-deep-cd19-cell-depletion\/","title":{"rendered":"Can autoimmune disease be cured by deep CD19+ cell depletion?"},"content":{"rendered":"<div>\n<p><b>J Immunol<\/b>. 2025 Mar 21:vkaf008. doi: 10.1093\/jimmun\/vkaf008. Online ahead of print.<\/p>\n<p><b>ABSTRACT<\/b><\/p>\n<p>Therapeutic B cell depletion with monoclonal antibodies targeting CD20 forced a rethink about the pathogenic role of B cells and plasma cells in autoimmune diseases; however, it was tempered by frequent clinical relapses or nonresponse to CD20-directed therapy. Here, we re-evaluate B cell depletion strategies in autoimmunity prompted by 4 recent advances. The first is analysis of clonal accumulations of CD20- CD19+ plasma cells making autoantibodies in patients with anti-CD20 refractory autoimmune disease. The second is the remarkable clinical remissions induced by anti-CD19 chimeric antigen receptor T cells in cases of anti-CD20 refractory autoimmunity. The third is evidence that CD19+ plasma cells comprise the majority of plasma cells in humans, are not terminally differentiated, are long-lived, and if self-reactive have potent capacity to capture autoantigens via their surface immunoglobulin and present major histocompatibility complex class II-bound peptides. The fourth is the role of autoantigen-binding B cells and CD19+ plasma cells as key antigen-presenting cells in &#8220;T cell-mediated&#8221; autoimmune disorders, type 1 diabetes and celiac disease. Viewing human memory B cells and plasma cells from this alternative perspective offers an explanation for why deep CD19 compartmental depletion may be effective at achieving complete and durable remissions in the autoantibody-positive autoimmune diseases as a group, irrespective of whether the autoantibody is pathogenic.<\/p>\n<p>PMID:<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/40116909\/?utm_source=WordPress&amp;utm_medium=rss&amp;utm_content=2985117R&amp;ff=20250321195338&amp;v=2.18.0.post9+e462414\">40116909<\/a> | DOI:<a href=\"https:\/\/doi.org\/10.1093\/jimmun\/vkaf008\">10.1093\/jimmun\/vkaf008<\/a><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>J Immunol. 2025 Mar 21:vkaf008. doi: 10.1093\/jimmun\/vkaf008. Online ahead of print. ABSTRACT Therapeutic B cell depletion with monoclonal antibodies targeting CD20 forced a rethink about the pathogenic role of B cells and plasma cells in autoimmune diseases; however, it was tempered by frequent clinical relapses or nonresponse to CD20-directed therapy. Here, we re-evaluate B cell &#8230; <a title=\"Can autoimmune disease be cured by deep CD19+ cell depletion?\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2025\/03\/22\/can-autoimmune-disease-be-cured-by-deep-cd19-cell-depletion\/\" aria-label=\"Read more about Can autoimmune disease be cured by deep CD19+ cell depletion?\">Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[42,71],"tags":[],"class_list":["post-27937","post","type-post","status-publish","format-standard","hentry","category-publicaciones","category-the-journal-of-immunology"],"_links":{"self":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/27937","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/comments?post=27937"}],"version-history":[{"count":0,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/27937\/revisions"}],"wp:attachment":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/media?parent=27937"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/categories?post=27937"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/tags?post=27937"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}